Date:8/14/2009

3 112,591 Prepaid expenses 737,779 301,898 Prepaid taxes 1,717,898 1,531,207 Other assets held for sale 10,828,631 10,904,842 Total current assets 96,849,849 106,554,754 PROPERTY, PLANT AND EQUIPMENT, net 10,796,643 10,274,643 OTHER ASSETS: Construction in progress 92,323,942 72,300,104 Construction deposits 4,695,601 2,586,302 Intangible assets, net 13,002,520 13,137,195 Other assets 73,050 87,541 Total other assets 110,095,113 88,111,142 Total assets $217,741,605 $204,940,539 L I A B I L I T I E S A N D S H A R E H O L DE R S' E Q U I T Y CURRENT LIABILITIES: Accounts payable $5,237,723 $ $6,283,849 Advances from customers - related parties 3,024,666 3,239,650 Wages and benefits payable 747,381 1,449,146 Other taxes payable 269,717 117,818 Contractor deposits 321,990 163,248 Contractor payables 14,229,565 11,871,456 Other payables 1,541,229 1,933,743 Other payables - related parties 213,263 6,373,900 Current portion of long term debt, related party 2,130,000 2,130,000 Liabilities directly associated with assets classified as held for sale 116,729 122,047 Total current liabilities 27,832,263 33,684,857 NON-CURRENT LIABILITIES Long term
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Tiens Biotech Group (USA) Reports First Quarter Results
2. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
3. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
4. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
5. Biotech Hot in July Driven by Positive Drug Data and Acquisitions
6. Cardinal Health Completes Biotech Acquisition
7. Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
8. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
9. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
10. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
11. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan